Skip to main
ATAI

ATAI Stock Forecast & Price Target

ATAI Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtaiBeckley is a clinical-stage biopharmaceutical company that has a strong focus on developing rapid-acting and effective mental health treatments, including BPL-003, VLS-01, and EMP-01. The company's potential for success is further supported by its strong pipeline, with BPL-003 expected to begin Phase 3 studies in 2Q26 and topline data guided for early 2029. While the company faces challenges and risks, including regulatory and commercial hurdles, its differentiated psychedelic assets and potential for integration into existing mental health treatment infrastructure make it a strong investment opportunity with a positive outlook.

Bears say

AtaiBeckley is developing novel therapies for mental health disorders, which is a growing and underserved market. However, the company's pipeline is still in early stages of clinical development and its success is not guaranteed, making it a high-risk investment. Additionally, reimbursement and utilization of their treatments may be a challenge, especially as shorter treatment durations may be preferred by patients and providers.

ATAI has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atai Life Sciences BV (ATAI) Forecast

Analysts have given ATAI a Strong Buy based on their latest research and market trends.

According to 7 analysts, ATAI has a Strong Buy consensus rating as of Jul 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atai Life Sciences BV (ATAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.